Not a wild goose chase: long-lasting MRSA negative status following eradication therapy for chronic MRSA infection in patients with cystic fibrosis

2021 ◽  
pp. 1-5
Author(s):  
Stefanie Vincken ◽  
Sylvia Verbanck ◽  
Shane Hanon ◽  
Eef Vanderhelst
Keyword(s):  
Cystic Fibrosis ◽  
Eradication Therapy ◽  
Mrsa Infection ◽  
Wild Goose

Cost of therapy for cystic fibrosis in different age groups with consideration to the respiratory tract infection and complications

2021 ◽  
Vol 31 (2) ◽  
pp. 238-249
Author(s):  
E. G. Furman ◽  
V. V. Shadrina ◽  
T. Yu. Maksimycheva ◽  
V. D. Sherman ◽  
E. I. Kondratyeva
Keyword(s):  
Cystic Fibrosis ◽  
Respiratory Tract ◽  
Pharmacoeconomic Analysis ◽  
Age Groups ◽  
Eradication Therapy ◽  
Cost Savings ◽  
Hypothetical Patient ◽  
Severity Of The Disease ◽  
Cost Of Drugs ◽  
The Cost

Despite the low prevalence of cystic fibrosis (CF), the costs of treating this disease are significant for the healthcare system. The aim of this economic study was to assess the total cost of drugs per year for children with CF, depending on age and course of the disease.Methods. For this pharmacoeconomic analysis, groups of “hypothetical” patients were formed according to the characteristics of the course of CF, taking into account the required volume of basic CF therapy, antibiotic therapy, and complications.Results. The cost of basic treatment for CF patients of different ages and disease progression in the hypothetical patient models can vary greatly. The cost of CF therapy increases significantly with age and Pseudomonas aeruginosa respiratory infection, especially in the patients with chronic infection, concomitant polyposis sinusitis, and low nutritional status.Conclusion. Patients with CF require regular follow-up with control of the microflora of the respiratory tract and effective eradication therapy for P. aeruginosa and other pathogenic microorganisms. Reducing infection rates and the severity of the disease can lead to significant cost savings.

scholarly journals Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis

2012 ◽  
Vol 106 (3) ◽  
pp. 356-360 ◽  
Author(s):  
Laura White ◽  
Ghazi Mirrani ◽  
Mark Grover ◽  
Judith Rollason ◽  
Adam Malin ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Eradication Therapy

Clinical Risk Factors Associated With Persistent MRSA Infection In US Cystic Fibrosis Patients

2010 ◽  
Author(s):  
Elliott C. Dasenbrook ◽  
Christian A. Merlo ◽  
Noah Lechtzin ◽  
Steven Strausbaugh ◽  
Michael W. Konstan ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cystic Fibrosis ◽  
Clinical Risk Factors ◽  
Factors Associated ◽  
Clinical Risk ◽  
Mrsa Infection

scholarly journals Pseudomonas aeruginosa eradication therapy and risk of acquiring Aspergillus in young children with cystic fibrosis

Thorax ◽  
2019 ◽  
Vol 74 (8) ◽  
pp. 740-748 ◽  
Author(s):  
Sabariah Noor Harun ◽  
Nicholas H G Holford ◽  
Keith Grimwood ◽  
Claire E Wainwright ◽  
Stefanie Hennig
Keyword(s):  
Cystic Fibrosis ◽  
Pseudomonas Aeruginosa ◽  
Young Children ◽  
Bronchoalveolar Lavage ◽  
Eradication Therapy ◽  
Positive Culture ◽  
Cross Sectional ◽  
Cross Sectional Analysis ◽  
Increased Risk ◽  
Sectional Analysis

BackgroundWhile Aspergillus detection rates in adults, adolescents and older children with cystic fibrosis (CF) have increased, the risk of acquiring this fungal pathogen in young children is unknown.AimTo determine the risk and explanatory factors of acquiring Aspergillus in children with CF by age 5 years.MethodsCross-sectional analysis of clinical, bronchoalveolar lavage and treatment data from the Australasian Cystic Fibrosis Bronchoalveolar Lavage study was used to identify predictive factors for detecting Aspergillus at age 5 years. A parametric repeated time-to-event model quantitatively described the risk and factors associated with acquiring Aspergillus and Pseudomonas aeruginosa from birth until age 5 years.ResultsCross-sectional analysis found that the number of P. aeruginosa eradication courses increased the odds of detecting Aspergillus at age 5 years (OR 1.61, 95% CI 1.23 to 2.12). The median (IQR) age for the first P. aeruginosa positive culture was 2.38 (1.32–3.79) years and 3.69 (1.68–4.74) years for the first Aspergillus positive culture. The risk of P. aeruginosa and Aspergillus events changes with time after the first year of study entry. It also decreases for P. aeruginosa after completing P. aeruginosa eradication (HR 0.15, 95% CI 0.00 to 0.79), but increases for Aspergillus events (HR 2.75, 95% CI 1.45 to 5.41). The risk of acquiring both types of events increases after having had a previous event.ConclusionIn young children with CF, completing P. aeruginosa eradication therapy and previous Aspergillus events are associated with increased risk of acquiring Aspergillus.

scholarly journals 189 Eradication therapy against early Pseudomonas aeruginosa infection in patients with Cystic Fibrosis

2006 ◽  
Vol 5 ◽  
pp. S44
Author(s):  
A.D. Grzejdziak ◽  
G. Cimino ◽  
S. Benedetti Valentine ◽  
V. D'Alù ◽  
S. Bertasi ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Pseudomonas Aeruginosa ◽  
Eradication Therapy ◽  
Pseudomonas Aeruginosa Infection

scholarly journals WS02.7 Initial and chronic MRSA infection in cystic fibrosis

2015 ◽  
Vol 14 ◽  
pp. S4
Author(s):  
D.F. Gilpin ◽  
S. Murdock ◽  
L.R. Hoffman ◽  
E. Vallières ◽  
S. McGrath ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Mrsa Infection
Sign in / Sign up

Export Citation Format

Share Document